Last reviewed · How we verify
LMP specific T cells
At a glance
| Generic name | LMP specific T cells |
|---|---|
| Sponsor | Baylor College of Medicine |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL) (PHASE1)
- Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE (PHASE1)
- Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder (PHASE2)
- Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta) (PHASE1)
- Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma (PHASE1)
- LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma (PHASE1)
- Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases (PHASE1)
- Allogeneic Stem Cell Transplantation With Adoptive Immunotherapy in Epstein-Barr Virus Positive Recurrent/Refractory Hodgkins Lymphoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LMP specific T cells CI brief — competitive landscape report
- LMP specific T cells updates RSS · CI watch RSS
- Baylor College of Medicine portfolio CI